Technology Platform is designed for targeted cancer destruction via harnessing the body’s immune memory against pathogens and childhood vaccines
, /PRNewswire-PRWeb/ — VerImmune, Inc. (“VerImmune”), a biotechnology company developing new therapeutic modalities that redirects the body’s pre-existing immunity toward cancer, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,285,203 entitled “Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses.” This patent protects VerImmune’s technology platform including critical compositions-of-matter and their use in treating cancer. The patent is also expected to provide protection until at least 2037, without accounting for potential Patent Term Extension (PTE).
“The award of this issued composition of matter patent in the United States with a significant lifespan is an important corporate milestone for our growing company, and marks the maturing of our robust intellectual property estate,” said Joshua Wang, Founding CEO of VerImmune.
VerImmune’s technology platform, discovered internally and wholly owned by VerImmune, provides unique products that harness the body’s pre-existing T-cell memory against pathogens and specifically redirects these responses to attack cancer. This is a potentially broadly applicable treatment paradigm, based on a single therapy, that can act against multiple human cancers due to the ubiquitous nature of pre-existing responses to childhood vaccines and/or past infections.
VerImmune is an biotechnology company developing a novel first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) technology platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or experience cancer treatment resistance. For more information, visit http://www.verimmune.com.
Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for VerImmune’s product candidates; and the business strategies and development plans of VerImmune. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include VerImmune’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, VerImmune does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Joshua Wang, VerImmune, +1 4434498836, email@example.com